The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The potential of the novel EED inhibitor pociredir in sickle cell disease
In this video, Caterina Minniti, MD, Albert Einstein College of Medicine, New York City, NY, briefly comments on the potential of pociredir, an inhibitor of embryonic ectoderm development (EED) that induces fetal hemoglobin (HbF) production, for the treatment of sickle cell disease (SCD). Dr Minniti notes that early data with this agent has been encouraging, and she looks forward to the results of the ongoing Phase Ib trial (NCT05169580). This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, hemoglobin F induction has long been recognized as the major determinant of sickle cell severity. So it’s no surprise that there are many, many oral hemoglobin F inducers that are being evaluated in the market. And if you think about it, one of the two gene therapies that has been approved does exactly that, turns on hemoglobin F. So we are very excited to follow the development of pociredir, as it has demonstrated in very early study in a Phase I, that there is a substantial increase in hemoglobin F and F cells...
Yes, hemoglobin F induction has long been recognized as the major determinant of sickle cell severity. So it’s no surprise that there are many, many oral hemoglobin F inducers that are being evaluated in the market. And if you think about it, one of the two gene therapies that has been approved does exactly that, turns on hemoglobin F. So we are very excited to follow the development of pociredir, as it has demonstrated in very early study in a Phase I, that there is a substantial increase in hemoglobin F and F cells. Because when we look at hemoglobin F, it’s not just the total amount that is important, but also its distribution. So hemoglobin F has to be present in most cells, and that’s why gene therapy is so effective. The data from the Phase Ib that they are running is not yet available, but what we know from what was presented at ASH last year is that it’s extremely promising. Hopefully, by the end of this year, we’ll have much more robust data on the 20 milligram dose. So, so far, it’s the 12 milligram dose that has been completed.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Pfizer, Novo Nordisk, Fulcrum.
